Germline pathogenic and likely pathogenic (P/LPs) variants in CHEK2 increase an individual’s risk of breast, colorectal, kidney, prostate, and thyroid cancer [2,3,4,5]. This evidence concerns the gene CHEK2 and thyroid gland carcinoma.